Schizophreniform disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 07 Aug 2026 04:02:47 +0000 en-US hourly 1 https://wordpress.org/?v=7.0.4 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Schizophreniform disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Randomized Controlled Trial of Cannabidiol vs Placebo Augmentation in Patients with First Episode Psychosis https://clinicaltrials.eu/trial/a-randomized-controlled-trial-of-cannabidiol-vs-placebo-augmentation-in-patients-with-first-episode-psychosis/ Mon, 03 Aug 2026 10:45:48 +0000 https://clinicaltrials.eu/trial/a-randomized-controlled-trial-of-cannabidiol-vs-placebo-augmentation-in-patients-with-first-episode-psychosis/ The study focuses on people who have experienced First Episode Psychosis, a condition where a person suddenly loses touch with reality and may see or hear things that are not there. Participants will continue taking their regular antipsychotic medication and will also receive either an oral dose of cannabidiol (often called CBD) or a placebo, which looks the same but contains no active ingredient.

The purpose of the trial is to see whether adding the study drug to standard treatment leads to greater overall improvement in symptoms after six weeks. Volunteers are assigned to one of the two groups by chance in a double‑blind manner, meaning neither the participants nor the study staff know who receives the active substance. Over the six‑week period, participants will attend regular visits where simple questionnaires and brief health checks are completed to track changes in mood, anxiety, daily functioning, and overall quality of life. After the treatment phase, participants will have a final follow‑up visit to assess any lasting effects.

]]> Study on the Effect of Clozapine and Drug Combination for Patients with Schizophrenia Experiencing First-Line Treatment Failure https://clinicaltrials.eu/trial/study-on-the-effect-of-clozapine-and-drug-combination-for-patients-with-schizophrenia-experiencing-first-line-treatment-failure/ Mon, 03 Aug 2026 10:16:03 +0000 https://clinicaltrials.eu/trial/study-on-the-effect-of-clozapine-and-drug-combination-for-patients-with-schizophrenia-experiencing-first-line-treatment-failure/ This clinical trial is focused on studying the effects of a new treatment approach for people with schizophrenia, schizoaffective disorder, or schizophreniform disorder. These are mental health conditions that can affect how a person thinks, feels, and behaves. The study will explore the impact of a six-week intensified medication treatment compared to the usual treatment for individuals who have experienced a first-time treatment failure with their initial medication. The medications being studied include clozapine, ziprasidone, amisulpride (also known as APD421), fluoxetine hydrochloride, perphenazine, paliperidone (also known as 9-hydroxyrisperidone), aripiprazole, promazine hydrochloride, diazepam, sulpiride, pyridoxine hydrochloride, chlorpromazine hydrochloride (also known as aminazine), fluphenazine decanoate, zuclopenthixol, risperidone, flupentixol decanoate (also known as flupenthixol decanoate), lurasidone, sertindole, haloperidol decanoate, pregabalin, brexpiprazole (also known as OPC-34712), cariprazine (also known as RGH-188), and asenapine.

The purpose of the study is to compare the effectiveness of this intensified treatment with the usual treatment in reducing symptoms of these conditions. Participants will receive either the intensified treatment or the usual treatment for six weeks. The study will monitor changes in symptom severity using a tool called the Positive and Negative Syndrome Scale (PANSS), which helps measure the severity of symptoms in these disorders. The study will also look at other aspects such as anxiety, depression, quality of life, and any side effects experienced during the treatment period.

Participants will be observed over a six-week period, during which they will have regular visits to assess their progress. The study aims to provide insights into whether an intensified treatment approach can offer better outcomes for individuals who have not responded well to their initial treatment. This research could help improve treatment strategies for people living with schizophrenia and related disorders.

]]>